title: [A 5-year follow-up study of antiviral effect of interferon in patients with chronic hepatitis C].
abstract: In order to discuss the anti-viral effects of IFN alpha-2a and IFN alpha-2b on chronic hepatitis C in a short and long period of time after treatment, 70 cases of chronic hepatitis C treated with IFN alpha-2a, 46 cases with IFN alpha-2b and 28 cases as controls had been investigated in this study. The follow-up time began from half to 5 years. The serum negative conversion rate of HCV RNA and the normalization of serum alanine transaminase(ALT) were detected at the end of treatment and up to 5 years after therapy. The negative seroconversion rate of HCV RNA and the serum ALT normalization were 67.14% and 70.00% respectively in IFN alpha-2a group and 69.56%, 71.71% respectively in IFN alpha-2b group at the end of the treatment. After 5-year follow-up, the above two Indexes were 35.71%, 47.14% respectively in IFN alpha-2a group, and 39.13%, 52.17% respectively in IFN alpha-2b group. The effectiveness in treated patients was higher than that of controls (P < 0.01 and P < 0.05). Recombinant IFN alpha-2a and IFN alpha-2b are effective medicines for HCV infection. And interferon therapy had a high short-term complete response but a low long-term complete response in the treatment of chronic hepatitis C. HCV genotype seems to be an important factor in determining the response rate of IFN treatment in patients with chronic hepatitis C.
authors.affiliation: 3rd Affilliated Hospital of Sun Yat-Sen University of Medical Sciences, Guangzhou 510630.
authors.forename: Y
authors.initials: Y
authors.lastname: Jiang
authors.forename: J
authors.initials: J
authors.lastname: Yao
authors.forename: W
authors.initials: W
authors.lastname: Peng
mesh_terms: D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D019698:Hepatitis C, Chronic / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins